Soleno Therapeutics (SLNO) said late Thursday that the European Medicines Agency validated the company's marketing authorization application for diazoxide choline tablets to treat hyperphagia in patients with Prader-Willi Syndrome.
The validation covers treatment of adults and children aged four years and above, the company said.
Soleno has received orphan drug designation for diazoxide choline in the European Union for Prader-Willi Syndrome treatment. This could provide the company with up to 10 years of market exclusivity in the region, if approved, it said.
Prader-Willi syndrome is a rare genetic neurodevelopmental disorder.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.